Reducing Point-of-Care Transfusion Requirements With Prolonged Desmopressin in High-Bleeding-Risk Cardiac Surgery: A Multicentre Randomized Controlled Trial (REDES-BLEED)

Rationale
Bleeding after cardiac surgery is a complication that might result in increased morbidity, mortality, and cost of cardiac surgery by 1.76 (confidence interval (CI), 1.64-1.90) times and a median increase in costs by Australian $33,338 (CI, $21,943-$38,415) [1]. Strategies and techniques to reduce postoperative bleeding in identified high-risk patients for bleeding after cardiac surgery might improve outcomes and resource utilization.
Desmopressin (DDAVP) is used as a hemostatic agent to prevent and treat bleeding in patients with mild hemophilia patients with von Willebrand's deﬁciency through stimulating the release of von Willebrand factor from endothelial cells.
Previous studies showed controversial results in terms of reduced transfusion requirements in patients with low risk for bleeding with post cardiopulmonary bypass (CPB) bleeding following prophylactic infusing desmopressin over 10 to 15 minutes after induction of anesthesia or protamine administration due to its positive effects on the coagulation system responsible for such bleeding. Contradictory, prophylactic desmopressin use demonstrated fewer transfusion requirements in patients treated with antiplatelets, which raises the need to examine its efficacy in high-risk cardiac surgery patients for perioperative bleeding. These controversial results might be attributed to delayed administration of desmopressin after evolving CPB-associated thrombocytopenia, platelet dysfunction, coagulation factor consumption and dilution, hyperfibrinolysis, and hypofibrinogenemia [2]
Concerns were raised about the associated transient decreases in systemic vascular resistance and blood pressure after desmopressin administration following discontinuing CPB and administering protamine, which might be related to the rapid infusion rate during the critical surgery stage.
The cost of a single dose of Desmopressin 0.3 ug/kg for a patient with an average weight of 70 Kg is about 82US$ which is cheaper than the alternative hemostatic agents proved to be effective in reducing bleeding and transfusion needs after cardiac surgery (e.g., fibrinogen concrete (average of 3 g = 1,167US$) and prothrombin complex concentrate (6,255US$ considering low fixed dosfixed-doseof 1040 IU F IX).
It is yet unclear if extended infusions of desmopressin started earlier before the development of CPB-associated coagulopathy and platelets dysfunction from anesthesia induction time and continued to the end of CPB before protamine administration would offer an "efficacy," "safety, and "cost-effective" benefits over placebo in patients with high risks for bleeding after cardiac surgery terms of the need for transfusion, cumulative postoperative 48-hour chest tube outputs, need for reoperation, thrombotic complications, 30-day mortality, hemodynamic stability, and urine output during and after completing infusion, and costs of the study drug and allogenic transfusion requirement. That raises the need to examine its impact on these crucial clinical outcomes.
Objective
The primary objective of this prospective multicentre randomized clinical trial (RCT) is, compared with placebo, to examine the impact of prolonged infusion desmopressin on reducing postoperative bleeding and the need for allogenic allogeneic transfusion in high-bleeding-risk cardiac surgery patients scheduled for elective cardiac surgical procedures using CPB. Secondary objectives include comparing placebo and desmopressin in terms of safety and cost-effectiveness.
Hypothesis
It is hypothesized that extended 'desmopressin' infusion compared to 'placebo' results in less postoperative bleeding and transfusion needs (more effective) and leads to less hemodynamic compromise (safer) and cheaper (cost-effective) in high-risk cardiac surgery patients.

开始日期2025-07-01

申办/合作机构

Imam Abdulrahman Bin Faisal University

[+1]

NCT06020495

/ Recruiting临床3期IIT

Systematic Use of DDAVP to Prevent Serum Sodium Overcorrection in Severe Hyponatremia: a Multicenter Open-label Randomized Controlled Trial

ICU patients with severe hyponatremia and a high risk of rapid SNa overcorrection.

开始日期2024-12-17

申办/合作机构

Assistance Publique des Hôpitaux de Paris SA

CTIS2023-507254-32-00

/ Recruiting临床3期IIT

DASSOH - Systematic use of DDAVP to prevent serum sodium overcorrection in severe hyponatremia : a multicenter open-label randomized controlled trial - APHP220676

开始日期2024-12-17

申办/合作机构

Assistance Publique Hopitaux De Paris

100 项与醋酸去氨加压素相关的临床结果

登录后查看更多信息

100 项与醋酸去氨加压素相关的转化医学

登录后查看更多信息

100 项与醋酸去氨加压素相关的专利（医药）

登录后查看更多信息

5,896

项与醋酸去氨加压素相关的文献（医药）

2025-12-01·CHILDS NERVOUS SYSTEM

Intracranial lobar germinoma presenting with refractory hypernatremia

Article

作者: Saini, Jitender ; Arivazhagan, A ; Sipani, Mahak ; Shashidhar, Abhinith ; Birua, Gyani Jail Singh ; Rao, Shilpa

Central nervous system germ cell tumours are most commonly seen in the midline structures. Eccentric germinomas are rare but can be found in the basal ganglia, lobar, brainstem, and cranial vault. We present a 14-year-old boy who presented with signs and symptoms of overt diabetes insipidus and a radiological diagnosis of left frontal high-grade glioma. Confirmative histopathology revealed germinoma. The patient had a resolution of hypernatremia post-surgery and maintained normal sodium homeostasis on a single dose of 0.1 mg of tablet desmopressin. This paper showcases a rare case of an eccentric central nervous system germinoma in a young male patient presenting with Diabetes Insipidus without any apparent sellar or suprasellar involvement.

2025-09-30·RAPID COMMUNICATIONS IN MASS SPECTROMETRY

Development and Validation of a Liquid Chromatography High‐Resolution Mass Spectrometry Method for Blood Desmopressin Quantification and Its Application in Hemophilia A Patients

Article

作者: Guillet, Benoît ; Serban, Adrian ; Pontis, Adeline ; Escal, Jean ; Josset, Laurie ; Hodin, Sophie ; Delavenne, Xavier ; Feliu, Catherine

ABSTRACT:

Desmopressin (DDAVP), which indirectly increases Coagulation Factor VIII concentrations in the blood, is a common treatment for bleeding disorders such as von Willebrand disease or hemophilia A. However, DDAVP exhibits significant variability in response due to interindividual differences in pharmacokinetics. Consequently, exploring its pharmacokinetics is of primary importance to better understand the relationship between DDAVP administration and therapeutic outcomes. To that end, the measurement of DDAVP concentration is essential. This article describes the development and validation of a liquid chromatography method coupled with high‐resolution mass spectrometry detection for quantifying DDAVP in human plasma. After sample pretreatment involving protein precipitation followed by solid‐phase extraction, quantification was based on the four most intense isotopes, utilizing targeted single ion monitoring, with a method range of 20–2000 pg.mL−1. For the four QC levels, accuracy and precision for both inter‐ and intra‐assay measurements were below 11.6% and 13.8%, respectively, meeting FDA recommendations. After validation, this method was applied to a cohort of 10 patients with a deficiency in Coagulation Factor VIII, who received 0.3 μg.kg−1 of desmopressin acetate. The mean volume of distribution at steady state was 18.8 L (CV% 26.7), the mean clearance was 7.8 L.h−1 (CV% 25.1), and the mean half‐life was 1.8 h (CV% 14.7). Offering valuable insights into the pharmacokinetics of DDAVP, this method will be useful for further studies and holds promise for optimizing treatment regimens in this patient population.

2025-09-01·PHYSIOLOGY & BEHAVIOR

The role of vasopressin deficiency in the fluid intake suppression hyper-responsivity to central glucagon-like peptide-1 in the Brattleboro rat

Article

作者: David, Sydney A ; Paul, Matthew J ; Daniels, Derek ; Brakey, Destiny J

Food and fluid intakes are physiologically and behaviorally intertwined; one often affects the other. Likewise, pharmacological manipulations that influence eating often affect drinking. For example, glucagon-like peptide-1 (GLP-1) suppresses both eating and fluid intake, but the respective elements of the GLP-1 system remain unparsed. The Brattleboro rat has emerged as a model to test for separable elements in the control of fluid or food intake. Brattleboro rats have hereditary hypothalamic vasopressin deficiency. To compensate for the resultant polyuria, they drink copious amounts of water. Eating, however, is similar to that observed in wildtype littermates and other Long Evans rats. Interestingly, treatment with a GLP-1 receptor agonist exendin-4 (Ex4) causes an exaggerated suppression of drinking in Brattleboro rats, but suppression of eating is comparable to wildtype controls. To test if this hyper-responsivity depends on the polydipsia in these rats, we normalized their drinking using desmopressin (ddAVP), a V2R agonist, before treatment with Ex4. ddAVP attenuated, but did not completely prevent, the hyper-responsivity to Ex4. Conversely, we treated wildtype rats with acute or chronic tolvaptan, a V2R antagonist, which generated a Brattleboro-like polydipsia, but this did not recapitulate the hyper-responsivity to Ex4 observed in Brattleboro rats. Based on these results, we conclude that polydipsia alone is insufficient to generate a hyper-responsive fluid intake suppression by Ex4, and that Brattleboro rats have at least some persistent hyper-responsivity to Ex4, even after alleviation of their polydipsia. These results provide important context for future studies using Brattleboro rats to study the GLP-1 system.

144

项与醋酸去氨加压素相关的新闻（医药）

2025-08-20

·GlobeNewswire-Health Care

Eton Pharmaceuticals to Participate at 2025 Wells Fargo Healthcare Conference

DEER PARK, Ill., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company’s executive leadership team will host 1x1 meetings at the 2025 Wells Fargo Healthcare Conference being held September 3-5, 2025 in Boston, MA. To schedule a 1x1 meeting with the Company, please contact your Wells Fargo institutional sales representative. About Eton Pharmaceuticals Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has eight commercial rare disease products: KHINDIVI™, INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has five additional product candidates in late-stage development: ET-600, Amglidia®, ET-700, ET-800 and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com. Investor Relations:Lisa M. Wilson, In-Site Communications, Inc.T: 212-452-2793E: lwilson@insitecony.com Source: Eton Pharmaceuticals. This press release was published by a CLEAR® Verified individual.

2025-08-07

·ir.etonpharma.com

Eton Pharmaceuticals Reports Second Quarter 2025 Financial Results

Q2 2025 product sales of $18.9 million , representing 108% growth over Q2 2024 and the 18th straight quarter of sequential product sales growth Q2 2025 basic and fully diluted GAAP EPS of $(0.10) , non-GAAP fully diluted EPS of $0.03 , and Adjusted EBITDA of $3.1 million Launched KHINDIVI™ (hydrocortisone) Oral Solution Reached 100 active INCRELEX® patients, ahead of previous guidance of year end Company projects reaching an annual revenue run rate of $80 million in Q3, one quarter ahead of previous guidance Management to hold conference call today at 4:30pm ET DEER PARK, Ill. , Aug. 07, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended June 30, 2025 . “Eton continues to execute on all fronts. During the second quarter, we received FDA approval for and subsequently launched KHINDIVI, marking our third commercial launch in 2025. As the first and only FDA-approved oral solution of hydrocortisone, KHINDIVI is a game changer for many pediatric patients. We were excited to finally bring this important treatment to the market and look forward to continuing to raise awareness of its availability,” said Sean Brynjelsen , CEO of Eton Pharmaceuticals . “Our strong commercial execution helped us deliver an impressive 108% revenue growth in the quarter, driven primarily by ongoing growth from ALKINDI SPRINKLE and the relaunches of INCRELEX and GALZIN. INCRELEX continues to track well ahead of our original expectations with 100 active patients at the end of July. We previously expected to reach this mark at the end of the year, so we are proud of the team’s hard work to hit this milestone well ahead of schedule. With these recent successes and the ongoing strength of our entire portfolio, we now expect to achieve an $80 million annual revenue run rate in the third quarter, one quarter ahead of our prior projections.” “In addition to executing on these three product launches and driving significant revenue growth, we continue to advance our pipeline programs, evaluate new business development opportunities and prepare for the potential approval and launch of ET-600 in the first quarter of 2026,” concluded Brynjelsen. Second Quarter and Recent Business Highlights 18th straight quarter of sequential growth in product sales and 108% growth over prior year quarter. Eton reported second quarter 2025 product sales of $18.9 million . Year-over-year revenue growth was driven primarily by continued growth in ALKINDI SPRINKLE® and the addition of revenues from INCRELEX and GALZIN. INCRELEX relaunch outperforming expectations; reached 100 active patients at the end of July. Eton’s ongoing engagement with the pediatric endocrinology community has helped drive awareness and clinical adoption of INCRELEX. The Company had a robust presence at key scientific conferences during the quarter, including Pediatric Endocrine Nurses Society (PENS), Pediatric Endocrine Society (PES), and Endocrine Society (ENDO), where it met with multiple advisory boards and Key Opinion Leaders, participated in a product symposium, hosted exhibit booths, and presented a new scientific poster featuring real-world registry data demonstrating the efficacy and safety of INCRELEX. Due to the strong execution of Eton’s commercial organization, INCRELEX has grown from 67 active patients in December 2024 to 100 active patients at the end of July, a target the Company initially expected to reach at the end of 2025. FDA approval and commercial launch of KHINDIVI, Eton’s 8th commercial product. On May 28th , Eton received FDA approval for KHINDIVI as a replacement therapy in pediatric patients five years of age and older with adrenocortical insufficiency. The product became commercially available in June, and the Company has received favorable early feedback from patients and prescribers. Eton is also working to develop a new formulation for patients aged four years and under. Eton has already manufactured registration batches of a new KHINDIVI formulation with substantially reduced levels of the inactive ingredients polyethylene glycol 400, propylene glycol, and glycerin, which Eton believes will allow for an expansion of the product’s approved population age. A pre-submission meeting with the FDA is scheduled for September, and the Company expects to file a supplement to the existing KHINDIVI New Drug Application (NDA) in the first half of 2026, which could allow for approval before the end of 2026. Continued growth of ALKINDI SPRINKLE. In the second quarter, ALKINDI SPRINKLE delivered strong sequential and year-over-year growth in revenue and patients on treatment. Through the second quarter, year-to-date new patient prescriptions exceeded the first two quarters of all prior years. In recent months, Eton had a prominent footprint at major healthcare professional congresses such as PENS, PES, ENDO, and Pediatric Endocrinology Society of Texas , Oklahoma , Louisiana , Arkansas (PESTOL), where the Company presented a new scientific poster showcasing real-world ALKINDI SPRINKLE safety and adherence data. Strong initial trajectory for GALZIN commercial relaunch. Eton relaunched GALZIN in March and believes it has now successfully transitioned most existing users to Eton’s distribution network. The Company’s launch has been well received by the Wilson disease community, which has expressed excitement about Eton’s efforts to broaden access to treatment with its $0 copay for eligible patients and high-touch specialty pharmacy distribution to help support medication adherence. The Company sees a significant long-term growth opportunity and has launched awareness and educational campaigns to target patients that have historically used over-the-counter zinc supplement products that are not FDA-approved for Wilson disease. NDA for ET-600 accepted by the FDA and second patent received. In July, ET-600's NDA was accepted for review by the FDA and assigned a Target Action Date of February 25, 2026 . Commercialization activities are already underway in anticipation of a potential first quarter 2026 launch. Also in July, the United States Patent and Trademark Office (USPTO) granted the Company a second patent covering ET-600's proprietary formulation of desmopressin oral solution. The patent expires in 2044 and is expected to be listed in the FDA Orange Book upon the product’s approval. Second Quarter Financial Results Net Revenue: Net revenues for the second quarter of 2025 were $18.9 million compared with $9.1 million in the prior year period, an increase of 108%. The growth was driven primarily by increased sales of ALKINDI SPRINKLE and the addition of sales from INCRELEX and GALZIN. The company now expects to achieve an approximately $80 million annual revenue run rate in the third quarter of 2025, one quarter ahead of previous projections. Gross Profit: Gross profit for the second quarter of 2025 was $11.9 million compared with $5.6 million in the prior year period, an increase of 112%. Adjusted gross profit, which adjusts for the impact of acquired inventory step-up adjustments and intangible amortization, was $14.1 million in the second quarter of 2025, representing an adjusted gross margin of 75% compared to adjusted gross profit of $5.9 million and adjusted gross margin of 65% in the prior year period. The margin improvement was primarily driven by continued growth of higher-margin ALKINDI SPRINKLE and the addition of high margin INCRELEX revenue. The Company continues to expect to report full year 2025 adjusted gross profit of approximately 70%. Research and Development (R&D) Expenses: R&D expenses for the second quarter of 2025 were $3.7 million compared to $3.0 million in the prior year period. R&D expenses for the second quarter of 2025 included a $2.2 million expense for the FDA application fee associated with the submission of the Company’s NDA for ET-600 and a $0.5 million expense related to the licensing of AMGLIDIA®.General and Administrative (G&A) Expenses: G&A expenses for the second quarter of 2025 were $9.7 million compared to $5.6 million in the prior year period. The increase was primarily attributable to an increase in sales and marketing expenses associated with the ongoing product launches and an increase in compensation and benefit expenses due to an increase in general and administrative headcount. Adjusted G&A expense, which removes share-based compensation, transaction related costs, and other one-time expenses, was $7.6 million in the quarter, compared with $4.9 million the prior year period. The Company expects Adjusted G&A expenses to remain flat or decline through the second half of 2025. Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (Adjusted EBITDA): Adjusted EBITDA for the second quarter of 2025 was $3.1 million compared to $(1.6) million in the prior year period. Net Income/Loss: Net loss for the second quarter of 2025 was $2.6 million or $0.10 per basic and diluted share compared to a net loss of $3.0 million or $0.12 per basic and diluted share in the prior year period. On a non-GAAP basis, the Company reported net income of $1.5 million or $0.03 per diluted share, for the second quarter of 2025 compared to a net loss of $1.9 million , or $0.08 per diluted share in the prior year period. For a reconciliation of GAAP net loss to Earnings Before Interest, Taxes, Depreciation and Amortization EBITDA (“EBITDA”), Adjusted EBITDA and adjusted Non-GAAP basic and fully diluted earnings per share to the most directly comparable GAAP financial measure, please see the tables below. Cash Position: As of June 30, 2025 , the Company had cash and cash equivalents of $25.4 million and generated $8.0 million of operating cash flow during the quarter. Subsequent to the second quarter, Eton received a $4.6 cash payment for the INCRELEX ex- U.S. licensing agreement executed in the first quarter. Conference Call and Webcast Information As previously announced, Eton Pharmaceuticals will host its second quarter 2025 conference call as follows: In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: investorrelations@etonpharma.com. The live webcast can be accessed on the Investors section of Eton’s website at https://ir.etonpharma.com. An archived webcast will be available on Eton’s website approximately two hours after the completion of the event and for 30 days thereafter. About Eton Pharmaceuticals Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has eight commercial rare disease products: KHINDIVI™, INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has five additional product candidates in late-stage development: ET-600, Amglidia®, ET- 700, ET -800 and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Eton to undertake certain activities and accomplish certain goals and objectives. These statements include but are not limited to statements regarding Eton’s business strategy, Eton’s plans to develop and commercialize its product candidates, the safety and efficacy of Eton’s product candidates, Eton’s plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for Eton’s product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Eton’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Eton’s development programs and financial position are described in additional detail in Eton’s filings with the Securities and Exchange Commission . All forward-looking statements contained in this press release speak only as of the date on which they were made. Eton undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Non-GAAP Financial Measures In addition to the Company’s results of operations determined in accordance with U.S. generally accepted accounting principles (GAAP), which are presented and discussed above, management also utilizes Adjusted EBITDA, an unaudited financial measure that is not calculated in accordance with GAAP, to evaluate the Company’s financial results and performance and to plan and forecast future periods. Adjusted EBITDA is considered a “non-GAAP” financial measure within the meaning of Regulation G promulgated by the SEC . Management believes that this non-GAAP financial measure reflects an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results, provides a more complete understanding of the Company’s results of operations and the factors and trends affecting its business. Management believes Adjusted EBITDA provides meaningful supplemental information regarding the Company’s performance because (i) it allows for greater transparency with respect to key metrics used by management in its financial and operational decision-making; (ii) it excludes the impact of non-cash or, when specified, non-recurring items that are not directly attributable to the Company’s core operating performance and that may obscure trends in the Company’s core operating performance; and (iii) it is used by institutional investors and the analyst community to help analyze the Company’s results. However, Adjusted EBITDA and any other non-GAAP financial measures should be considered as a supplement to, and not as a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. Further, non-GAAP financial measures used by the Company and the way they are calculated may differ from the non-GAAP financial measures or the calculations of the same non-GAAP financial measures used by other companies, including the Company’s competitors. Adjusted EBITDAThe Company defines Adjusted EBITDA as net loss, excluding the effects of stock-based compensation and expenses, interest, taxes, depreciation, amortization, investment loss, net, and, if any and when specified, other non-recurring income or expense items. Management believes that the most directly comparable GAAP financial measure to Adjusted EBITDA is net loss. Adjusted EBITDA has limitations and should not be considered as an alternative to gross profit or net loss as a measure of operating performance or to net cash provided by (used in) operating, investing, or financing activities as a measure of ability to meet cash needs. Investor Relations: Lisa M. Wilson , In-Site Communications, Inc. T: 212-452-2793 E: lwilson@insitecony.com Source: Eton Pharmaceuticals

上市批准财报申请上市

2025-08-03

·信狐药迅

扬子江ED新药妥诺达非片和上海恒润达生润达基奥仑赛两个1类新药上市获批| 新获批(7.28-8.3）

每周药品注册获批数据，分门别类呈现，一目了然。(7.28-8.3）新药上市申请药品名称企业注册分类受理号盐酸妥诺达非片扬子江药业集团有限公司1CXHS2300035利培酮口溶膜齐鲁制药有限公司2.2CXHS2200060国;CXHS2200060利培酮口溶膜齐鲁制药有限公司2.2CXHS2200059国;CXHS2200059润达基奥仑赛注射液上海恒润达生生物科技股份有限公司1CXSS2300098索卡佐利单抗注射液兆科(广州)肿瘤药物有限公司2.2CXSS2400065新药临床申请药品名称企业注册分类受理号富马酸奥比特嗪肠溶微丸胶囊深圳市真兴医药技术有限公司1CXHL2500512VB19055片浙江扬厉医药技术有限公司1CXHL2500509VB19055片浙江扬厉医药技术有限公司1CXHL2500508VB19055片浙江扬厉医药技术有限公司1CXHL2500507VB19055片浙江扬厉医药技术有限公司1CXHL2500506注射用DYX116江苏德源药业股份有限公司1CXHL2500500注射用DYX116江苏德源药业股份有限公司1CXHL2500499HRS-2162注射液福建盛迪医药有限公司1CXHL2500467玛仕度肽注射液信达生物制药(苏州)有限公司1CXHL2500459玛仕度肽注射液信达生物制药(苏州)有限公司1CXHL2500458玛仕度肽注射液信达生物制药(苏州)有限公司1CXHL2500457注射用硼[10B]法仑中子科学(重庆)研究院有限公司2.2CXHL2500532CB345杭州成邦医药科技有限公司2.2CXHL2500495CB345杭州成邦医药科技有限公司2.2CXHL2500494QLM2012齐鲁制药有限公司2.2CXHL2500489QLM2012齐鲁制药有限公司2.2CXHL25004881536A北京康联智汇科技有限公司2.2CXHL2500484TQC3302吸入喷雾剂正大天晴(广州)医药有限公司2.3CXHL2500476TQC3302吸入喷雾剂正大天晴(广州)医药有限公司2.3CXHL2500475TQC3302吸入喷雾剂正大天晴(广州)医药有限公司2.3CXHL2500474AFN1204注射液合肥阿法纳生物科技有限公司1.2CXSL2500367AFN1213注射液合肥阿法纳生物科技有限公司1.2CXSL2500365SM2275注射液珠海烁星生物医药科技有限公司1CXSL2500443IBI363信达生物制药(苏州)有限公司1CXSL2500435IBI363信达生物制药(苏州)有限公司1CXSL2500434注射用MHB088C明慧医药(杭州)有限公司1CXSL2500433注射用MHB039A明慧医药(杭州)有限公司1CXSL2500432注射用HB0043上海华奥泰生物药业股份有限公司1CXSL2500431HEC-301注射液东莞市东阳光生物药研发有限公司1CXSL2500426IBI363信达生物制药(苏州)有限公司1CXSL2500421IBI363信达生物制药(苏州)有限公司1CXSL2500420SSGJ-706注射液沈阳三生制药有限责任公司1CXSL2500419SSGJ-706注射液沈阳三生制药有限责任公司1CXSL2500418斯乐韦米单抗注射液重庆智翔金泰生物制药股份有限公司1CXSL2500414重组抗VEGF人源化单抗注射液百奥泰生物制药股份有限公司1CXSL2500360重组抗VEGF人源化单抗注射液百奥泰生物制药股份有限公司1CXSL2500359注射用重组A型肉毒毒素乐普健糖药业(重庆)有限公司2.4CXSL2500427仿制药申请药品名称企业注册分类受理号西格列汀二甲双胍缓释片浙江和泽医药科技股份有限公司3CYHS2403016马来酸阿塞那平舌下片哈尔滨三联药业股份有限公司3CYHS2402669倍他米松磷酸钠注射液成都瑞尔医药科技有限公司3CYHS2401520盐酸溴己新注射液辰欣药业股份有限公司3CYHS2401309美索巴莫注射液福州基石医药科技有限公司3CYHS2401134腺苷钴胺胶囊华北制药股份有限公司3CYHS2401022美索巴莫注射液浙江昂利康制药股份有限公司3CYHS2401003奥美沙坦酯口崩片吉林省德商药业股份有限公司3CYHS2400991奥美沙坦酯口崩片吉林省德商药业股份有限公司3CYHS2400990注射用尼可地尔福建泽瑞药业有限公司3CYHS2400972注射用尼可地尔福建泽瑞药业有限公司3CYHS2400971二羟丙茶碱注射液福建品腾药业有限公司3CYHS2400958布美他尼注射液成都瑞尔医药科技有限公司3CYHS2400943布美他尼注射液成都瑞尔医药科技有限公司3CYHS2400942注射用尼可地尔广东海赫生物医药科技有限公司3CYHS2400899硫酸沙丁胺醇注射液江苏开元药业有限公司3CYHS2400862帕拉米韦注射液浙江诚意药业股份有限公司3CYHS2400760二羟丙茶碱注射液浙江赛默制药有限公司3CYHS2400726利奈唑胺氯化钠注射液大翔医药集团有限公司3CYHS2400655西咪替丁注射液山西惠达林曦医药科技有限公司3CYHS2400649重酒石酸间羟胺注射液海南爱科制药有限公司3CYHS2400647氯化钙注射液山东齐都药业有限公司3CYHS2400618氯化钾缓释片重庆药友制药有限责任公司3CYHS2400544二羟丙茶碱注射液浙江同伍生物医药有限公司3CYHS2400523盐酸溴己新注射液峨眉山通惠制药有限公司3CYHS2400503地氯雷他定口服溶液圣嘉(滨海)生物医药科技有限公司3CYHS2400494酮咯酸氨丁三醇注射液江苏明圣康源药业有限公司3CYHS2400490己酮可可碱缓释片石药集团中诺药业(石家庄)有限公司3CYHS2400489小儿复方氨基酸注射液(19AA-I)四川科伦药业股份有限公司3CYHS2400484盐酸多巴酚丁胺注射液西藏邦臣药业集团有限公司3CYHS2400385硫酸阿托品注射液河南普瑞药业有限公司3CYHS2400371复方匹可硫酸钠颗粒成都倍特得诺药业有限公司3CYHS2400354门冬氨酸钾注射液广州合和医药有限公司3CYHS2400339二羟丙茶碱注射液湖南尔康制药股份有限公司3CYHS2400311美沙拉秦肠溶缓释颗粒深圳市瑞华制药技术有限公司3CYHS2400302美沙拉秦肠溶缓释颗粒深圳市瑞华制药技术有限公司3CYHS2400301尼莫地平口服溶液常州四药制药有限公司3CYHS2400255复方聚乙二醇(3350)电解质散翎耀生物科技(上海)有限公司3CYHS2400249注射用苯唑西林钠山东如至生物医药科技有限公司3CYHS2400211注射用苯唑西林钠山东如至生物医药科技有限公司3CYHS2400210联苯苄唑溶液福元药业有限公司3CYHS2400194盐酸甲氧氯普胺注射液湖北民康药业集团有限公司3CYHS2400187西格列汀二甲双胍缓释片浙江昂利康制药股份有限公司3CYHS2400188氯化钾口服溶液沈阳天邦药业有限公司3CYHS2400164氨氯地平贝那普利胶囊北京万辉双鹤药业有限责任公司3CYHS2400074米诺地尔搽剂合肥华威药业有限公司3CYHS2400045米诺地尔搽剂合肥华威药业有限公司3CYHS2400046坎地氢噻片重庆圣华曦药业股份有限公司3CYHS2400019地氯雷他定口服溶液江苏东科康德药业有限公司3CYHS2303649盐酸奈福泮注射液山东豪瑞恩制药有限公司3CYHS2303644氯化钾颗粒南京海鲸药业股份有限公司3CYHS2303494复方醋酸钠林格注射液广东科伦药业有限公司3CYHS2303486复方醋酸钠林格注射液广东科伦药业有限公司3CYHS2303485盐酸拉贝洛尔注射液南京海科瑞医药科技有限公司3CYHS2303445盐酸拉贝洛尔注射液南京海科瑞医药科技有限公司3CYHS2303444硫酸镁注射液成都百裕制药股份有限公司3CYHS2303410地氯雷他定口服溶液山东新华鲁抗医药有限公司3CYHS2303390氯化钾颗粒石家庄康力药业有限公司3CYHS2303358氯化钾颗粒石家庄康力药业有限公司3CYHS2303357盐酸西替利嗪口服溶液安徽四环科宝制药有限公司3CYHS2303346复方聚乙二醇(3350)电解质散圣嘉(滨海)生物医药科技有限公司3CYHS2303308盐酸昂丹司琼片杭州沐源生物医药科技有限公司3CYHS2303264盐酸昂丹司琼片杭州沐源生物医药科技有限公司3CYHS2303263西咪替丁注射液广州市联瑞制药有限公司3CYHS2303168倍他米松磷酸钠注射液江苏神龙药业有限公司3CYHS2302928倍他米松磷酸钠注射液江苏神龙药业有限公司3CYHS2302927马来酸噻吗洛尔滴眼液扬州中宝药业股份有限公司3CYHS2302766尼麦角林片江西大生医药科技有限公司3CYHS2302722腺苷钴胺胶囊成都慧德医药科技有限公司3CYHS2302622草酸艾司西酞普兰口服溶液北京海步医药科技有限公司3CYHS2302553普瑞巴林口服溶液山东道齐生物医药科技有限公司3CYHS2302471复方奥美拉唑干混悬剂浙江同伍生物医药有限公司3CYHS2302230复方奥美拉唑干混悬剂浙江同伍生物医药有限公司3CYHS2302229布美他尼注射液中山万汉制药有限公司3CYHS2302195地喹氯铵含片湖北午时医药研究院有限公司3CYHS2301269西格列汀二甲双胍缓释片南通联亚药业股份有限公司3CYHS2301143西格列汀二甲双胍缓释片南通联亚药业股份有限公司3CYHS2301142西格列汀二甲双胍缓释片南通联亚药业股份有限公司3CYHS2301141注射用卡非佐米江苏豪森药业集团有限公司3CYHS2101695国;CYHS2101695注射用卡非佐米江苏豪森药业集团有限公司3CYHS2101694国;CYHS2101694注射用卡非佐米江苏豪森药业集团有限公司3CYHS2101693国;CYHS2101693氧河南上益气体有限公司4CYHS2403396氧(液态)林德(上海)半导体气体有限公司4CYHS2403307氧芒市芒源气体有限公司4CYHS2403293平衡盐溶液(供灌注用)中国大冢制药有限公司4CYHS2403066硫酸氨基葡萄糖胶囊西安信百欣医药科技有限公司4CYHS2402890阿戈美拉汀片江苏诺泰澳赛诺生物制药股份有限公司4CYHS2401993地夸磷索钠滴眼液广州大光制药有限公司4CYHS2401977地夸磷索钠滴眼液广州大光制药有限公司4CYHS2401976左卡尼汀口服溶液江苏盈科生物制药有限公司4CYHS2401827尼可地尔片本溪匠成医药科技有限公司4CYHS2401673富马酸依美斯汀滴眼液广州仁恒医药科技股份有限公司4CYHS2401666罗沙司他胶囊郑州德迈药业有限公司4CYHS2401609罗沙司他胶囊郑州德迈药业有限公司4CYHS2401608盐酸贝尼地平片福建海西新药创制股份有限公司4CYHS2401585硫酸镁钠钾口服用浓溶液江苏广承药业有限公司4CYHS2401514达可替尼片山东朗诺制药有限公司4CYHS2401510达可替尼片山东朗诺制药有限公司4CYHS2401509平衡盐溶液(供灌注用)海南爱科制药有限公司4CYHS2401492洛索洛芬钠凝胶贴膏上海延安药业(湖北)有限公司4CYHS2401506地屈孕酮片浙江高跖医药科技股份有限公司4CYHS2401484聚乙烯醇滴眼液苏州欧康维视生物科技有限公司4CYHS2401461恩格列净片浙江宏元药业股份有限公司4CYHS2401379盐酸多柔比星脂质体注射液河北天成药业股份有限公司4CYHS2401341替米沙坦片河北山姆士药业有限公司4CYHS2401366替米沙坦片河北山姆士药业有限公司4CYHS2401364替米沙坦片河北山姆士药业有限公司4CYHS2401362兰索拉唑肠溶胶囊北京福元医药股份有限公司4CYHS2401264兰索拉唑肠溶胶囊北京福元医药股份有限公司4CYHS2401263培哚普利氨氯地平片(III)成都硕德药业有限公司4CYHS2401223枸橼酸托法替布缓释片合肥华方医药科技有限公司4CYHS2401181普拉洛芬滴眼液湖北远大天天明制药有限公司4CYHS2401172氨甲环酸片杭州康恩贝制药有限公司4CYHS2401139洛索洛芬钠凝胶膏浙江赛默制药有限公司4CYHS2401124帕拉米韦氯化钠注射液山东齐都药业有限公司4CYHS2401090帕拉米韦氯化钠注射液山东齐都药业有限公司4CYHS2401089硫酸镁钠钾口服用浓溶液珠海横琴国研医药科技有限公司4CYHS2401077哌柏西利胶囊北京双鹭药业股份有限公司4CYHS2401020哌柏西利胶囊北京双鹭药业股份有限公司4CYHS2401019富马酸福莫特罗吸入溶液成都海德康药业有限公司4CYHS2401023贝前列素钠片浙江美迪深生物医药有限公司4CYHS2401009醋酸加尼瑞克注射液辰欣药业股份有限公司4CYHS2400951奥卡西平口服混悬液上海奥科远制药有限公司4CYHS2400969缬沙坦氨氯地平片(I)河北三森药业有限公司4CYHS2400898硫酸氨基葡萄糖胶囊山西德元堂药业有限公司4CYHS2400891阿司匹林肠溶片河北汇德旭盛医药科技有限公司4CYHS2400873盐酸尼卡地平注射液北京新美泰克医药科技有限公司4CYHS2400858他达拉非片湘北威尔曼制药股份有限公司4CYHS2400852他达拉非片湘北威尔曼制药股份有限公司4CYHS2400851他达拉非片湘北威尔曼制药股份有限公司4CYHS2400850屈螺酮炔雌醇片武汉九珑人福药业有限责任公司4CYHS2400812他达拉非片贵州圣济堂制药有限公司4CYHS2400799他达拉非片贵州圣济堂制药有限公司4CYHS2400798洛索洛芬钠凝胶膏宁波美舒医药科技有限公司4CYHS2400796富马酸伏诺拉生片海南皇隆制药股份有限公司4CYHS2400783富马酸伏诺拉生片海南皇隆制药股份有限公司4CYHS2400782培哚普利氨氯地平片(III)杭州康恩贝制药有限公司4CYHS2400763维格列汀片新天地药业股份有限公司4CYHS2400749卡泊三醇搽剂湖北恒安芙林药业股份有限公司4CYHS2400725间苯三酚注射液山东新时代药业有限公司4CYHS2400744亚叶酸钙注射液国药一心制药有限公司4CYHS2400711美沙拉秦肠溶片合肥立方制药股份有限公司4CYHS2400696左西孟旦注射液重庆德诚永道医药有限公司4CYHS2400658复方氨基酸注射液(17AA-III)四川太平洋药业有限责任公司4CYHS2400640盐酸伐地那非片山东华铂凯盛生物科技有限公司4CYHS2400621非那雄胺片江苏润邦药业有限公司4CYHS2400615美阿沙坦钾片重庆圣华曦药业股份有限公司4CYHS2400613美阿沙坦钾片重庆圣华曦药业股份有限公司4CYHS2400612盐酸咪达普利片国药集团容生制药有限公司4CYHS2400609伊布替尼胶囊南京正大天晴制药有限公司4CYHS2400607富马酸伏诺拉生片石家庄龙泽制药股份有限公司4CYHS2400574盐酸莫西沙星片四川迪菲特药业有限公司4CYHS2400576克立硼罗软膏江苏万高药业股份有限公司4CYHS2400540孟鲁司特钠颗粒牡丹江恒远药业股份有限公司4CYHS2400561西罗莫司片杭州中美华东制药有限公司4CYHS2400467盐酸缬更昔洛韦片浙江车头制药股份有限公司4CYHS2400441注射用醋酸西曲瑞克江苏诺泰澳赛诺生物制药股份有限公司4CYHS2400431硫酸镁钠钾口服用浓溶液沈阳天邦药业有限公司4CYHS2400395利培酮口崩片河北龙海药业有限公司4CYHS2400351奥卡西平口服混悬液四川科瑞德制药股份有限公司4CYHS2400340苯磺酸氨氯地平片山东普瑞曼药业有限公司4CYHS2400299玻璃酸钠滴眼液河北宏鑫堂药业有限公司4CYHS2400246瑞舒伐他汀依折麦布片(I)石家庄四药有限公司4CYHS2400179小儿法罗培南钠颗粒湖南明瑞制药股份有限公司4CYHS2400181阿托伐他汀钙片重庆药友制药有限责任公司4CYHS2400159阿托伐他汀钙片重庆药友制药有限责任公司4CYHS2400158非那雄胺片山东淄博新达制药有限公司4CYHS2400153注射用丁二磺酸腺苷蛋氨酸福安药业集团烟台只楚药业有限公司4CYHS2400108硫酸镁钠钾口服用浓溶液南京正科医药股份有限公司4CYHS2400111中/长链脂肪乳注射液(C6-24)安徽富邦药业有限公司4CYHS2400055中/长链脂肪乳注射液(C6-24)安徽富邦药业有限公司4CYHS2400056夫西地酸钠软膏北京诚济制药股份有限公司4CYHS2400012注射用硫酸艾沙康唑山东齐都药业有限公司4CYHS2400011泊沙康唑注射液海南海灵化学制药有限公司4CYHS2400021复方聚乙二醇电解质散(III)广州一品红制药有限公司4CYHS2303671醋酸去氨加压素注射液华夏生生药业(北京)有限公司4CYHS2303668醋酸去氨加压素注射液华夏生生药业(北京)有限公司4CYHS2303667美沙拉秦肠溶片杭州煌森生物科技有限公司4CYHS2303657缬沙坦氨氯地平片(I)翎耀生物科技(上海)有限公司4CYHS2303604复方氨基酸注射液(18AA-VII)华夏生生药业(北京)有限公司4CYHS2303621注射用哌拉西林钠他唑巴坦钠温州海鹤药业有限公司4CYHS2303514夫西地酸乳膏苏州高迈药业有限公司4CYHS2303446二十碳五烯酸乙酯软胶囊扬子江药业集团有限公司4CYHS2303326罗沙司他胶囊昆山龙灯瑞迪制药有限公司4CYHS2303227罗沙司他胶囊昆山龙灯瑞迪制药有限公司4CYHS2303226氨氯地平阿托伐他汀钙片北京双鹭药业股份有限公司4CYHS2303191盐酸屈他维林注射液安徽长江药业有限公司4CYHS2303166硫酸镁钠钾口服用浓溶液浙江众延医药科技有限公司4CYHS2303157聚乙二醇钠钾散南京海纳制药有限公司4CYHS2303083玻璃酸钠滴眼液海南斯达制药有限公司4CYHS2303007玻璃酸钠滴眼液海南斯达制药有限公司4CYHS2303006注射用生长抑素深圳新声药业有限公司4CYHS2302912克立硼罗软膏杭州领业医药科技有限公司4CYHS2302855注射用盐酸万古霉素重庆药友制药有限责任公司4CYHS2302876氢溴酸替格列汀片浙江星月药物科技有限公司4CYHS2302811氢溴酸替格列汀片浙江星月药物科技有限公司4CYHS2302810琥珀酸普芦卡必利片江西欧氏药业有限责任公司4CYHS2302785琥珀酸普芦卡必利片江西欧氏药业有限责任公司4CYHS2302784硫酸镁钠钾口服用浓溶液广州市亿源医药有限公司4CYHS2302781克林霉素磷酸酯外用溶液安徽省先锋制药有限公司4CYHS2302676克林霉素磷酸酯外用溶液安徽省先锋制药有限公司4CYHS2302675奈妥匹坦帕洛诺司琼胶囊齐鲁制药有限公司4CYHS2302494聚乙二醇4000散澳美制药(海南)有限公司4CYHS2302490吗啉硝唑氯化钠注射液仁合益康集团有限公司4CYHS2302168硫酸镁钠钾口服用浓溶液河北合渡药业有限公司4CYHS2302007奈妥匹坦帕洛诺司琼胶囊四川科伦药业股份有限公司4CYHS2301047注射用氯诺昔康江西人可医药科技有限公司4CYHS2300962注射用多种维生素(12)重庆药友制药有限责任公司6CYHS1400454渝;CYHS1400454去氧胆酸注射液江苏润恒制药有限公司3CYHL2500099酮洛芬凝胶贴膏湖南派格兰药业有限公司3CYHL2500097注射用重组凝血因子Ⅷ(猪序列)庄亚(北京)生物科技有限公司3.4CXSL2500353进口申请药品名称企业注册分类受理号甲磺酸仑伐替尼胶囊Eisai Europe Limited2.4JXHS2400083甲磺酸仑伐替尼胶囊Eisai Europe Limited2.4JXHS2400082甲磺酸兰泽替尼片Janssen-Cilag International NV2.4JXHS2400009替尔泊肽注射液Eli Lilly Nederland B.V.5.1JXHS2400102替尔泊肽注射液Eli Lilly Nederland B.V.5.1JXHS2400101替尔泊肽注射液Eli Lilly Nederland B.V.5.1JXHS2400100替尔泊肽注射液Eli Lilly Nederland B.V.5.1JXHS2400099塞利尼索片Karyopharm Therapeutics Inc.5.1JXHS2400084奥拉帕利片AbbVie Limited5.1JXHS2400081奥拉帕利片AbbVie Limited5.1JXHS2400080玻璃体内注射用曲安奈德WAKAMOTO PHARMACEUTICAL CO., LTD.5.1JXHS2400027伊匹木单抗注射液Bristol-Myers Squibb Pharma EEIG3.1JXSS2400093伊匹木单抗注射液Bristol-Myers Squibb Pharma EEIG3.1JXSS2400092纳武利尤单抗注射液Bristol-Myers Squibb Pharma EEIG3.1JXSS2400091纳武利尤单抗注射液Bristol-Myers Squibb Pharma EEIG3.1JXSS2400090瑞利珠单抗注射液Alexion Europe SAS3.1JXSS2400087瑞利珠单抗注射液Alexion Europe SAS3.1JXSS2400086吸入用七氟烷Piramal Critical Care, Inc.5.2JYHS2400004盐酸伐地那非口腔崩解片Chanelle Medical Unlimited Company5.2JYHS2300138盐酸去氧肾上腺素注射液M/s Mankind Pharma Limited5.2JYHS2300133特立氟胺片Aurobindo Pharma Limited5.2JYHS2300126特立氟胺片Aurobindo Pharma Limited5.2JYHS2300125达格列净片KRKA, d.d.5.2JYHS2300105AZD0780薄膜衣片AstraZeneca AB1JXHL2500106他克莫司滴眼液SENJU PHARMACEUTICAL CO., LTD.2.4JXHL2500104注射用FelzartamabBiogen Idec Research Limited1JXSL2500082GHZ339注射液Novartis Pharma AG1JXSL2500081TARA-002Protara Therapeutics, Inc.2.2JXSL2500070中药相关申请药品名称企业注册分类受理号金丹附延颗粒江西华太药业有限公司2.3CXZL2500029参蒲盆安颗粒江苏康缘药业股份有限公司1.1CXZS2400017注：橙色字体部分结论为不批准或收到通知件；

上市批准申请上市

100 项与醋酸去氨加压素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02235	醋酸去氨加压素	H01BA02	DB00035

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
夜尿	美国	Acerus Pharmaceuticals Corp.	2017-03-03
尿崩症	中国	Ferring Pte Ltd.	2001-06-29
神经性尿崩症	美国	Ferring Pharmaceuticals, Inc.	1984-03-30
夜间遗尿症	美国	Ferring Pharmaceuticals, Inc.	1978-02-21

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
多尿	临床3期	日本	Ferring Pharmaceuticals A/S	2016-09-01
原发性夜尿症	临床3期	加拿大	Ferring Pharmaceuticals A/S	2004-07-01
消化道出血	临床2期	阿根廷	Laboratorio Elea Phoenix SA	2013-04-01
直肠腺癌	临床2期	阿根廷	Laboratorio Elea Phoenix SA	2013-04-01
膀胱过度活动症	临床2期	美国	Ferring Pharmaceuticals A/S	2013-01-01
乳腺癌	临床2期	阿根廷	Laboratorio Elea Phoenix SA	2011-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


Company_Website 人工标引	N/A	神经性尿崩症	75	ET-600	選顧簾選糧餘鹹餘積願(鏇鹽廠網醖膚壓網憲鏇) = positive results from its bioequivalence study of ET-600. 築齋構願網膚餘範構蓋 (蓋憲願築積窪構觸鹽鏇 )	积极	2025-03-14
NCT04420585 (CTgov)	临床4期	夜间遗尿症 \| 原发性夜尿症 \| 半规管裂综合征 ... 更多	8	Desmopressin	願構鬱壓鏇壓艱鬱構築(遞壓窪鑰壓積壓繭醖憲) = 壓網繭願繭壓簾積繭網鬱膚網觸膚鬱蓋觸鹽夢 (醖遞範鹹膚齋齋糧壓憲, 26.2) 更多	-	2024-05-07
NCT01982760 (CTgov)	临床2期	瘀斑	14	DDAVP (DDAVP)	壓遞願壓壓齋夢淵夢鏇(餘製夢繭膚製鏇選衊襯) = 積觸窪膚壓齋選築艱醖鹹網蓋夢選餘鑰齋憲簾 (憲鏇構鬱鏇繭積簾憲蓋, 範遞醖願夢鏇餘廠淵憲 ~ 廠憲構顧網艱糧廠鏇積) 更多	-	2023-08-16
				DDAVP (No DDAVP)	壓遞願壓壓齋夢淵夢鏇(餘製夢繭膚製鏇選衊襯) = 壓選鬱憲夢鏇鑰蓋觸夢鹹網蓋夢選餘鑰齋憲簾 (憲鏇構鬱鏇繭積簾憲蓋, 鑰夢膚遞糧齋鹽糧餘齋 ~ 衊膚願鹽醖獵築齋襯鹹) 更多
ISRCTN67038373 (DASH, Pubmed)	临床2期	脑出血 antiplatelet drugs	54	Desmopressin	簾構艱範壓製構獵獵壓(積選網鹽鏇艱醖簾鹹廠) = 淵簾艱鹹鬱餘願觸夢壓襯襯壓艱鏇鑰糧鬱積範 (衊築夢願簾窪鑰選窪衊 ) 更多	-	2023-07-01
				Placebo	簾構艱範壓製構獵獵壓(積選網鹽鏇艱醖簾鹹廠) = 築鹹願壓網憲鑰餘齋膚襯襯壓艱鏇鑰糧鬱積範 (衊築夢願簾窪鑰選窪衊 ) 更多
NCT00981682 (CTgov)	临床3期	夜尿	376	SER120	選範顧廠衊膚憲簾憲觸(願壓鏇繭壓壓鹹餘顧壓) = 襯鑰淵觸觸襯鬱齋餘淵願獵繭齋衊築觸膚選鹽 (築築夢範網窪獵醖膚鏇, 2.3) 更多	-	2021-01-20
NCT01900704 (DB4, CTgov)	临床3期	夜尿	810	SER120 750 ng (SER120 750 ng)	選網積夢築蓋觸構廠衊(構製願願網繭齋鬱蓋醖) = 鬱憲鬱廠醖壓糧鹽觸製膚夢遞蓋簾顧繭築廠廠 (壓觸鹽窪衊蓋網築選壓, 0.06) 更多	-	2020-11-09
				SER120 1500 ng (SER120 1500 ng)	選網積夢築蓋觸構廠衊(構製願願網繭齋鬱蓋醖) = 廠鑰淵選壓鹽遞網鑰範膚夢遞蓋簾顧繭築廠廠 (壓觸鹽窪衊蓋網築選壓, 0.06) 更多
NCT00937378 (CTgov)	临床3期	夜尿	326	SER120 (SER120)	選築網襯糧築廠蓋鬱鑰(構鬱遞範構積窪鑰廠鏇) = 簾鏇繭齋顧簾觸選壓製築範積廠鬱壓醖廠築繭 (憲鏇衊鑰遞獵遞襯簾襯, 0.8) 更多	-	2020-10-22
				Placebo (Placebo)	選築網襯糧築廠蓋鬱鑰(構鬱遞範構積窪鑰廠鏇) = 觸積積齋壓醖窪鬱衊鏇築範積廠鬱壓醖廠築繭 (憲鏇衊鑰遞獵遞襯簾襯, 0.8) 更多
NCT01357356 (CTgov)	临床2/3期	夜尿	750	Placebo	鏇艱齋壓簾簾夢獵憲製(蓋壓窪餘願醖壓蓋齋糧) = 壓夢顧遞顧衊鑰衊膚選積觸壓範顧膚積簾選齋 (鏇獵壓構觸積積鹹網願, 0.07) 更多	-	2020-10-08
NCT01623206 (Pubmed \| Invest New Drugs) 人工标引	临床2期	出血 \| 直肠癌	32	dDAVP	選製選憲廠糧壓鑰鏇顧(餘糧鑰齋築製鑰鹹顧鑰) = 鹹鏇獵鏇憲鏇夢顧衊遞壓築遞窪膚鹹遞蓋鹹構 (鹽醖鏇觸艱夢鹽積衊窪 ) 更多	积极	2020-10-01
NCT00937859 (CTgov)	临床3期	夜尿	301	SER120 (SER120)	壓蓋醖構齋觸壓鏇顧製(憲艱糧艱壓廠憲膚築衊) = 觸衊積選鹽積鏇觸鏇網鏇積選鑰繭壓憲簾壓廠 (鬱鹽築製選鹽襯製衊積, 0.9) 更多	-	2020-09-18
				Placebo (Placebo)	壓蓋醖構齋觸壓鏇顧製(憲艱糧艱壓廠憲膚築衊) = 糧艱選餘願範醖壓構獵鏇積選鑰繭壓憲簾壓廠 (鬱鹽築製選鹽襯製衊積, 1.0) 更多